000132456 001__ 132456
000132456 005__ 20240229105017.0
000132456 0247_ $$2doi$$a10.1002/ijc.31168
000132456 0247_ $$2pmid$$apmid:29159866
000132456 0247_ $$2ISSN$$a0020-7136
000132456 0247_ $$2ISSN$$a1097-0215
000132456 037__ $$aDKFZ-2018-00144
000132456 041__ $$aeng
000132456 082__ $$a610
000132456 1001_ $$0P:(DE-HGF)0$$aBabaei, Masoud$$b0$$eFirst author
000132456 245__ $$aAdministration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study.
000132456 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000132456 3367_ $$2DRIVER$$aarticle
000132456 3367_ $$2DataCite$$aOutput Types/Journal article
000132456 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659445404_15547
000132456 3367_ $$2BibTeX$$aARTICLE
000132456 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132456 3367_ $$00$$2EndNote$$aJournal Article
000132456 520__ $$aThe advantage of adjuvant chemotherapy (ACT) for treating Stage III colon cancer patients is well established and widely accepted. However, many patients with Stage III colon cancer do not receive ACT. Moreover, there are controversies around the effectiveness of ACT for Stage II patients. We investigated the administration of ACT and its association with overall survival in resected Stage II (overall and stratified by low-/high-risk) and Stage III colon cancer patients in three European countries including The Netherlands (2009-2014), Belgium (2009-2013) and Sweden (2009-2014). Hazard ratios (HR) for death were obtained by Cox regression models adjusted for potential confounders. A total of 60244 resected colon cancer patients with pathological Stages II and III were analyzed. A small proportion (range 9-24%) of Stage II and over half (range 55-68%) of Stage III patients received ACT. Administration of ACT in Stages II and III tumors decreased with higher age of patients. Administration of ACT was significantly associated with higher overall survival in high-risk Stage II patients (in The Netherlands (HR; 95%CI = 0.82 (0.67-0.99), Belgium (0.73; 0.59-0.90) and Sweden (0.58; 0.44-0.75)), and in Stage III patients (in The Netherlands (0.47; 0.43-0.50), Belgium (0.46; 0.41-0.50) and Sweden (0.48; 0.43-0.54)). In Stage III, results were consistent across subgroups including elderly patients. Our results show an association of ACT with higher survival among Stage III and high-risk Stage II colon cancer patients. Further investigations are needed on the selection criteria of Stages II and III colon cancer patients for ACT.
000132456 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132456 588__ $$aDataset connected to CrossRef, PubMed,
000132456 7001_ $$00000-0002-4950-0554$$aBalavarca, Yesilda$$b1
000132456 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b2
000132456 7001_ $$aLemmens, Valery$$b3
000132456 7001_ $$avan Erning, Felice N$$b4
000132456 7001_ $$avan Eycken, Liesbet$$b5
000132456 7001_ $$aVaes, Evelien$$b6
000132456 7001_ $$aSjövall, Annika$$b7
000132456 7001_ $$aGlimelius, Bengt$$b8
000132456 7001_ $$aUlrich, Cornelia M$$b9
000132456 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b10
000132456 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b11$$eLast author
000132456 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31168$$gVol. 142, no. 7, p. 1480 - 1489$$n7$$p1480 - 1489$$tInternational journal of cancer$$v142$$x0020-7136$$y2018
000132456 909CO $$ooai:inrepo02.dkfz.de:132456$$pVDB
000132456 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132456 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-4950-0554$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132456 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132456 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000132456 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000132456 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132456 9141_ $$y2018
000132456 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132456 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132456 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132456 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132456 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000132456 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132456 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132456 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132456 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132456 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132456 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132456 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000132456 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132456 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000132456 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132456 980__ $$ajournal
000132456 980__ $$aVDB
000132456 980__ $$aI:(DE-He78)C070-20160331
000132456 980__ $$aI:(DE-He78)G110-20160331
000132456 980__ $$aI:(DE-He78)L101-20160331
000132456 980__ $$aUNRESTRICTED